{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:57:19Z","timestamp":1740149839890,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12328-024-02032-8","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T10:02:06Z","timestamp":1724148126000},"page":"1067-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-7983","authenticated-orcid":false,"given":"Ken","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-5860","authenticated-orcid":false,"given":"Takehiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-9729","authenticated-orcid":false,"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5998-9998","authenticated-orcid":false,"given":"Ayako","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-5212","authenticated-orcid":false,"given":"Yuki","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7071-1945","authenticated-orcid":false,"given":"Tatsuma","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-2857","authenticated-orcid":false,"given":"Norifumi","family":"Harimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-6827","authenticated-orcid":false,"given":"Hideaki","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7173-7945","authenticated-orcid":false,"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-4331","authenticated-orcid":false,"given":"Toshio","family":"Uraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"2032_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-021-00237-y","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang Y, Lu LC, Guan Y, et al. Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp Hematol Oncol. 2021;10:45.","journal-title":"Exp Hematol Oncol"},{"key":"2032_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12328-022-01644-2","volume":"15","author":"T Hoshino","year":"2022","unstructured":"Hoshino T, Naganuma A, Furusawa A, et al. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. Clin J Gastroenterol. 2022;15:776\u201383.","journal-title":"Clin J Gastroenterol"},{"key":"2032_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12957-022-02691-2","volume":"20","author":"Y Hidaka","year":"2022","unstructured":"Hidaka Y, Tomita M, Desaki R, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol. 2022;20:228.","journal-title":"World J Surg Oncol"},{"key":"2032_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12328-022-01744-z","volume":"16","author":"A Fukunaga","year":"2023","unstructured":"Fukunaga A, Takata K, Itoh S, et al. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis. Clin J Gastroenterol. 2023;16:224\u20138.","journal-title":"Clin J Gastroenterol"},{"key":"2032_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.21873\/anticanres.16239","volume":"43","author":"T Miyata","year":"2023","unstructured":"Miyata T, Sugi K, Horino T, et al. Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res. 2023;43:943\u20137.","journal-title":"Anticancer Res"},{"key":"2032_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000529405","volume":"40","author":"K Kurisaki","year":"2023","unstructured":"Kurisaki K, Soyama A, Hara T, et al. Pathologic complete response after chemotherapy with atezolizumab plus bevacizumab for hepatocellular carcinoma with tumor thrombus in the main portal trunk. Dig Surg. 2023;40:84\u20139.","journal-title":"Dig Surg"},{"key":"2032_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40792-023-01678-9","volume":"9","author":"R Tsunemitsu","year":"2023","unstructured":"Tsunemitsu R, Tabuchi M, Sakamoto S, et al. Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy. Surg Case Rep. 2023;9:93.","journal-title":"Surg Case Rep"},{"issue":"10","key":"2032_CR8","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2147\/JHC.S433598","volume":"24","author":"H-M Hsu","year":"2023","unstructured":"Hsu H-M, Tsai H-I, Lee W-C, Wang C-C, Ming-Chin Y, Lin S-M, Lin C-Y, Chi-Huan W, Lee C-W. Theextended surgical concepts for hepatocellular carcinoma in the era of immune checkpoint inhibitors. J Hepatocell Carcinoma. 2023;24(10):1873\u201380.","journal-title":"J Hepatocell Carcinoma."},{"key":"2032_CR9","first-page":"475","volume":"83","author":"M Kudo","year":"2021","unstructured":"Kudo M, Aoki T, Ueshima K, et al. Upfront systemic therapy with subsequent curative conversion for intermediate-stage hepatocellular carcinoma: atezolizumab+bevacizumab curative conversion (ABC conversion) therapy. KanTanSui. 2021;83:475\u2013783.","journal-title":"KanTanSui"},{"key":"2032_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1159\/000519749","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer. 2021;10:539\u201344.","journal-title":"Liver Cancer"},{"key":"2032_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11523-022-00921-x","volume":"17","author":"T Niizeki","year":"2022","unstructured":"Niizeki T, Tokunaga T, Takami Y, et al. Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a propensity score matching analysis. Target Oncol. 2022;17:643\u201353.","journal-title":"Target Oncol"},{"key":"2032_CR12","doi-asserted-by":"publisher","first-page":"12325","DOI":"10.1002\/cam4.5931","volume":"12","author":"S Shimose","year":"2023","unstructured":"Shimose S, Iwamoto H, Shirono T, et al. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2023;12:12325\u201335.","journal-title":"Cancer Med"},{"key":"2032_CR13","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"2032_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450\u20136.","journal-title":"Nature"},{"key":"2032_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599\u2013611.","journal-title":"Nat Med"},{"key":"2032_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1053\/j.gastro.2023.02.042","volume":"165","author":"M Espinoza","year":"2023","unstructured":"Espinoza M, Muquith M, Lim M, et al. Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150. Gastroenterology. 2023;165:286-288.e4.","journal-title":"Gastroenterology"},{"key":"2032_CR17","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s00432-023-04590-9","volume":"149","author":"TJ Brown","year":"2023","unstructured":"Brown TJ, Mamtani R, Gimotty PA, et al. Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. J Cancer Res Clin Oncol. 2023;149:2345\u201354.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2032_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","volume":"7","author":"M Rimini","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7:100591.","journal-title":"ESMO Open."},{"key":"2032_CR19","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. eClinicalMedicine. 2024;70:102536.","journal-title":"eClinicalMedicine"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-02032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-024-02032-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-02032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T08:23:52Z","timestamp":1731054232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-024-02032-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1007\/s12328-024-02032-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for being included in this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}